Généthon, the AFM-Telethon laboratory, has received the authorization delivered by the National Agency for Drug Safety (ANSM) to become a pharmaceutical manufacturer.
Its production center, Généthon BioProd, is now authorized to produce drugs for innovative treatments. This is a first for a laboratory created by an association of patients and financed thanks to the generosity of the public, and a new stage in the emergence of innovative treatments for rare diseases.
